

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Grant, Elfrida R., et. al.

Serial No. : 09/922,658

Art Unit: 1614

Filed : August 6, 2001

Examiner:

For : 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

December 13, 2001

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)


(Signature)

December 13, 2001

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.


☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached);
or

☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:



action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached);
or

☐ Please charge Deposit Account No. 10-0750/
the fee of \$180.00 as set forth in §1.17(p).


☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.



☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Applicants wish to make the Examiner aware of co-pending application serial number 09/922,874.


Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1483/MHM. This form is submitted in triplicate.

Respectfully submitted,



Myra H. McCormack
Reg. No. 36602
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATED: December 13, 2001





PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TECH CENTER 1800/2900

JAN 10 2002

RECEIVED

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	09/922658
Filing Date	August 6, 2001
First Named Inventor	Elfida R. Grant, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1483

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	6	Ahn, N., et. al. (1991) J. Biol. Chem. 266:4220-4227 ✓	
	7	Allessandrini, A.I., et. al. (1999) Proc Natl Acad Sci USA 96:12866-9. ✓	
	8	Anderson, N., et. al. (1990) Nature 343:651-653 ✓	
	9	Bading, H., Greenberg, M.E. (1991) Science 253:912-914 ✓	
	10	Callaway, J., et. al. (1999) Stroke 12:2704-2712 ✓	
	11	Canzoniero, L., et al. J. (1996) J. Neurosci. Res. 45:226-236 ✓	
	12	Cheng, Y., et. al. (1998) J. Clin. Invest. 101:1992-1999 ✓	
	13	Chijiwa, T., et. al. (1990) J. Biol. Chem. 265:5267-5272 ✓	
	14	Courtney, M., et. al. (1990) J. Neurosci. 10:3873-3879 ✓	
	15	Crews, C., Allessandrini, A., Erikson, R. (1992) Science 258:478-480 ✓	
	16	Desdouits-Magnen, J., et. al. (1998) J. Neurochem. 70:524-530 ✓	
	17	Enslin, H., et al. (1996) Proc Natl Acad Sci USA 93:10803-10808 ✓	
	18	Favata, M.F., et al., (1998) J. Biol. Chem. 273:18623-18632 ✓	
	19	Fiore, R.S., et al. (1993) J Neurochem 61:1626-1633 ✓	
	20	Grobin, A.C., (1999) Brain Research 827:1-11 ✓	
	21	Heath, D., Vink, R. (1999) J. Neurosurg. 90:504-509 ✓	
	22	Henry, J., et al. (1998) J. Med. Chem. 41:4196-4198 ✓	
	23	Hu, B., Wieloch, T. (1994) J. Neurochem 62:1357-1367 ✓	
	24	Inhorn, R., Majerus, P. (1987) J. Biol. Chem. 262:15946-15952 ✓	
	25	Ishii, T., et al. (1993) J. Biol. Chem. 268:2836-2843 ✓	
	26	Jaiswal, R., et al. (1994) Mol. Cell. Biol. 14:6944-6953 ✓	
	27	Jones-Velleneuve, et al. (1982) J. Cell. Biol. 94:253-262 ✓	
	28	Jones-Velleneuve, et al. (1983) Mol. Cell Biol. 4:2271-2279	
	29	Jovanoic, J., et al. (1996) Proc. Natl. Acad. Sci. USA 93:3679-3683	
	30	Kindy, M. (1993) J Chereb Blood Flow Metab 13:372-377	
	31	Kobayashi, E., et al. (1989) Biochem. Biophys. Res. Commun. 159:548-553	
	32	Kurino, M., et al. (1995) J Neurochem 65:1282-1289	
	33	Lander, H., et al. (1996) J. Biol. Chem. 271:19705-19709	
	34	Laurie, D., et al. (1995) Brain Res. Mol. Brain Res. 32:94-108	
	35	Lee, J., et al. (1994) Nature 372:739-746	
	36	Lev, S., et al. (1995) Nature 376:737-745	
	37	Li, B., et al. (1999a) Eur. J. Biochem. 262:211-217	
	38	Li, M., et al. (1999b) Brain Res. 1999:44-52	
	39	McBurney, M.W., et al. (1982) Dev. Biol. 89:503-508	
	40	Meldrum, B., Garthwaite, J. (1990) Trends Pharmacol Sci 11:379-387	
	41	Monyer, H., et. al. (1994) Neuron 12:529-540	
	42	Monyer, H., et. al. (1992) Science 256:1217-1221	
	43	Moodie, S., et al. (1993) Science 260:1658-1661	
	44	Morley, p., et al. (1995) J. Neurochem. 65:1093-1099	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	09/922658
Filing Date	August 6, 2001
First Named Inventor	Elfida R. Grant, et.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1483

TECH CENTER 1630/2000

JAN 10 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	45	Murray, B., et al. (1998) Proc. Natl. Acad. Sci. USA 95:11975-11980	
	46	Onoda, T., et al. (1989) J. Nat. Prod. 52:1252-1257	
	47	Papin, C., et al. (1995) Oncogene 10:1647-1651	
	48	Park, C., et al. (1988) Ann. Neurol. 24:543-551	
	49	Pazos, a., et al. (1999) Brain Res. 846:186-195	
	50	Pleasure, S., Lee, V. -Y. (1993) Journal of Neurosci. Res. 35:585-602	
	51	Pleasure, S., et al. (1992) J. Neurosci. 12:1802-1815	
	52	Ray, W.J., Gottlieb, D. I. (1993) Biochem. Biophys. Res. Comm. 197:1475-1482	
	53	Rootwelt, T., et al. (1998) J. Neurochem. 71:1544-1553	
	54	Rosen, L., et al. (1994) Neuron 12:1207-1221	
	55	Sakagami, H., Kondo, H. (1993) Brain Res Mol Brain Res 19:215-218	
	56	Sakakibara, Y., et al. (2000) Neurosci Lett 281:111-114	
	57	Sattler, R., et al. (1999) Science 284:1845-1848	
	58	Schneeggenburger, R., et al. (1993) Neuron 11:133-143	
	59	Schwartz-Bloom, R., et al. (1998) J Chereb Blood Flow Metab 18:548-558	
	60	Sola, C., et al. (1999) J. Neurosci. Res. 57:651-652	
	61	Stanciu, M., et al. (2000) J. Biol. Chem. 275:12200-12206	
	62	Standaert, D., et al. (1994) J. Comp. Neurol. 343:1-16	
	63	Takahashi, M., et al. (1998) J. Pharmacol. Exp. Ther. 287:559-566	
	64	Tatlisumak, T., et al. (1998) Stroke 29:1952-1958	
	65	Tokumitsu, H., et al. (1990) J. Biol. Chem. 265:4315-4320	
	66	Turetsky, D.M., et al. (1993) J. Neurobiol. 24:1157-1169	
	67	Turski, L., et al. (1998) Proc. Natl. Acad. Sci. USA 95:10960-10965	
	68	Tymianski, M., et al. (1993) J. Neurosci. 13:2085-2104	
	69	Vanhoutte, P., et al. (1999) Mol. Cell Biol 19:136-146	
	70	Wasterlain, C., et al. (1996) Stroke 27:1236-1240	
	71	Xia, Z., et al. (1995) Science 270:1326-1331	
	72	Xia, Z., et al. (1996) J. Neurosci. 16:5425-5436	
	73	Yang, D. D., et al. (1997) Nature 389:865-870	
	74	Yang, Y., et al. (1998) Brain Res. 804:169-176	
	75	Zheng, C., et al. (1993) J. Biol. Chem. 268:23933-23939	
	76	Brint, et al. (1988) J. Cereb Blood Flow Metab 8:474-485	
	77	Aronowski, et al. (1994) Stroke 25:2235-2240	
	78	Skaper SD, Facci L, Strijbos PJ. (2000) "Neuronal protein kinase signaling cascades and excitotoxic cell death". Ann NY Acad Sci 939:11-22.	
	79	D'Orlando C, Fellay B, Schwaller B, Salicio V, Bloc A, Gotzos V, Celio M., (2001) "Calretinin and calbindin D-28K delay the onset of cell death after excitotoxic stimulation in transfected P19 cells," Brain Research 909 145-158	
	80	Grant, ER, Errico, MA, Emanuel SL, Benjamin D, McMillian MK, Wadsworth SA, Zivin RA, Zhong Z, (2001) "Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells," Biochemical Pharmacology 62:283-296	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.